High-Density Lipoprotein Functionality as a New Pharmacological Target on Cardiovascular Disease: Unifying Mechanism That Explains High-Density Lipoprotein Protection Toward the Progression of Atherosclerosis
- PMID: 29528874
- DOI: 10.1097/FJC.0000000000000573
High-Density Lipoprotein Functionality as a New Pharmacological Target on Cardiovascular Disease: Unifying Mechanism That Explains High-Density Lipoprotein Protection Toward the Progression of Atherosclerosis
Abstract
The formation of the atherosclerotic plaque that is characterized by the accumulation of abnormal amounts of cholesterol-loaded macrophages in the artery wall is mediated by both inflammatory events and alterations of lipid/lipoprotein metabolism. Reverse transport of cholesterol opposes the formation and development of atherosclerotic plaque by promoting high density lipoprotein (HDL)-mediated removal of cholesterol from peripheral macrophages and its delivery back to the liver for excretion into the bile. Although an inverse association between HDL plasma levels and the risk of cardiovascular disease (CVD) has been demonstrated over the years, several studies have recently shown that the antiatherogenic functions of HDL seem to be mediated by their functionality, not always associated with their plasma concentrations. Therefore, assessment of HDL function, evaluated as the capacity to promote cell cholesterol efflux, may offer a better prediction of CVD than HDL levels alone. In agreement with this idea, it has recently been shown that the assessment of serum cholesterol efflux capacity (CEC), as a metric of HDL functionality, may represent a predictor of atherosclerosis extent in humans. The purpose of this narrative review is to summarize the current evidence concerning the role of cholesterol efflux capacity that is important for evaluating CVD risk, focusing on pharmacological evidences and its relationship with inflammation. We conclude that HDL therapeutics are a promising area of investigation but strategies for identifying efficacy must move beyond the idea of simply raising static HDL-cholesterol levels and toward methods of measuring the dynamics of HDL particle remodeling and the generation of lipid-free apolipoprotein A-I (apoA-I). In this way, apoA-I, unlike mature HDL, can promote the greatest extent of cholesterol efflux relieving cellular cholesterol toxicity and the inflammation it causes.
Similar articles
-
Cholesterol efflux and reverse cholesterol transport.Handb Exp Pharmacol. 2015;224:181-206. doi: 10.1007/978-3-319-09665-0_4. Handb Exp Pharmacol. 2015. PMID: 25522988 Review.
-
Novel formulation of a reconstituted high-density lipoprotein (CSL112) dramatically enhances ABCA1-dependent cholesterol efflux.Arterioscler Thromb Vasc Biol. 2013 Sep;33(9):2202-11. doi: 10.1161/ATVBAHA.113.301981. Epub 2013 Jul 18. Arterioscler Thromb Vasc Biol. 2013. PMID: 23868939
-
CSL112 (Apolipoprotein A-I [Human]) Enhances Cholesterol Efflux Similarly in Healthy Individuals and Stable Atherosclerotic Disease Patients.Arterioscler Thromb Vasc Biol. 2018 Apr;38(4):953-963. doi: 10.1161/ATVBAHA.118.310538. Epub 2018 Feb 8. Arterioscler Thromb Vasc Biol. 2018. PMID: 29437574 Free PMC article. Clinical Trial.
-
High-density lipoprotein-based drug discovery for treatment of atherosclerosis.Expert Opin Drug Discov. 2015;10(8):841-55. doi: 10.1517/17460441.2015.1051963. Epub 2015 May 28. Expert Opin Drug Discov. 2015. PMID: 26022101 Review.
-
Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice.Circulation. 2004 Jun 29;109(25):3215-20. doi: 10.1161/01.CIR.0000134275.90823.87. Epub 2004 Jun 14. Circulation. 2004. PMID: 15197147
Cited by
-
Association between cholesterol efflux capacity and peripheral artery disease in coronary heart disease patients with and without type 2 diabetes: from the CORDIOPREV study.Cardiovasc Diabetol. 2021 Mar 25;20(1):72. doi: 10.1186/s12933-021-01260-3. Cardiovasc Diabetol. 2021. PMID: 33766036 Free PMC article.
-
Circulating HDL levels control hypothalamic astrogliosis via apoA-I.J Lipid Res. 2018 Sep;59(9):1649-1659. doi: 10.1194/jlr.M085456. Epub 2018 Jul 10. J Lipid Res. 2018. PMID: 29991652 Free PMC article.
-
HDL-Mediated Cholesterol Efflux and Plasma Loading Capacities Are Altered in Subjects with Metabolically- but Not Genetically Driven Non-Alcoholic Fatty Liver Disease (NAFLD).Biomedicines. 2020 Dec 18;8(12):625. doi: 10.3390/biomedicines8120625. Biomedicines. 2020. PMID: 33352841 Free PMC article.
-
Revealing the Role of High-Density Lipoprotein in Colorectal Cancer.Int J Mol Sci. 2021 Mar 25;22(7):3352. doi: 10.3390/ijms22073352. Int J Mol Sci. 2021. PMID: 33805921 Free PMC article. Review.
-
The role of blood cholesterol quality in patients with advanced cancer receiving immune checkpoint inhibitors.Cancer Immunol Immunother. 2023 Jul;72(7):2127-2135. doi: 10.1007/s00262-023-03398-3. Epub 2023 Feb 24. Cancer Immunol Immunother. 2023. PMID: 36828963 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical